Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a ...
CRN

Proofpoint CEO On Closing ‘Watershed’ $1.8B Hornetsecurity Deal, IPO Plans

Proofpoint’s acquisition of Microsoft 365 security specialist Hornetsecurity—a $1.8 billion deal completed Monday—sets the ...
autoevolution

All-New Mercedes-Benz GLB Breaks Cover, It's Electric Only

The Mercedes-Benz GLB with EQ Technology joins its compact siblings, the GLA and GLC, being available with an electric ...